A chemical engineer at the University of Massachusetts-Amherst believes a different approach is needed for understanding breast cancer and metastasis, one based more on engineering than traditional medical research disciplines.
Shelly Peyton, Ph.D., has been awarded a three-year, $590,000 grant from the National Science Foundation to do just that: to study how various types of breast cancer interact with different human tissues-tissues she and her research team can create in the laboratory. Peyton said by studying how, where, and why breast cancer metastasizes, she hopes to develop patientspecific therapies that can attack the cancer as it tries to seek out and colonize these diverse tissues. (Peyton's grant is from a subset of the National Science Foundation, the Physical and Engineering Sciences in Oncology.)
Cancer research was not on Peyton's radar when studying for her Ph.D. "I don't have a family history [of] cancer at all, so I'm not motivated by that," said Peyton. Most of her graduate and postdoc work focused on cardiovascular tissue engineering.
Later, while at MIT, she worked with biological engineers who were building macroporous three-dimensional scaffolds as a model system to study adult stem cell migration. "We were interested in seeing if there was just some physical characteristics of the scaffold that we could change that would maximize stem cell migration into the middle of the scaffold. We investigated if we could predict how long the healing time for a patient with a large wound would be, based on the physical characteristics of that scaffold." After conferring with colleagues about the tissue tropism phenomenon, which also happens in all cancers, she became interested in exploring it further. Peyton's approach is a variation of the Old Saw; if you're in a hole, it might be time to stop digging. Peyton would never describe breast cancer metastasis research as being in a hole, but it is definitely in a sort of rut. "I do view a lot of cancer biology to be sort of stuck on this genetic approach," said Peyton.
Peyton doesn't believe it's necessary for cancer researchers to stop digging altogether, but maybe to work in a different plot. "I've noticed many researchers try to find a gene or a protein that's misregulated, and then try to focus their careers on studying how to stop that gene from causing cancer. We have been doing that for a while; I don't think that's going to work. I've wondered if the solution might be to combine what we already know about genes, protein, and cancer with my approach." Jacob Scott, M.D., from the Department of Radiation Oncology and Integrative Mathematical Oncology at the H. Lee Moffitt Cancer Center in Tampa, Fla., thinks Peyton may be on to something. "I think this research represents a rational next step forward that will definitely serve to advance our knowledge of metastasis," said Scott.
"Bringing more physical science-oriented investigators to the fray in our war on cancer brings with it fresh insights that would not otherwise be represented. By using state-of-the-art techniques in tissue engineering, Peyton will be able to deconvolute the otherwise dizzying complexity inherent in the study of metastasis." Scott is also a graduate of the Oxford University Centre for Mathematical Biology.
Peyton said the goals of her research are to unravel the questions about which type of cancer moves to each type of tissue and to find a way to stop the spread of the disease. "The critical question for me is where does it go and why. We think there are some mechanical relationships there, but we don't know what they are yet."
Peyton has divided her work into three broad objectives. The first one is to "quantify subtype-specific tissue tropism in breast cancer in 'engineered metastatic microenvironments.'" To study this aspect, she and her research team will design highly controllable, reproducible biomaterial systems, which mimic the in vivo physicochemical properties of metastatic tissue.
"Using 12 human breast cancer cell lines that represent the clinically relevant disease subtypes and quantitative 3D microscopy, this proposal will systematically quantify the migration and proliferation response to these controlled physicochemical cues," said Peyton.
Peyton is not the first researcher to investigate tissue tropism and cancer. More than 100 years ago, Stephen Paget reported on secondary breast cancer metastases occurring in specific organs. "To this day, there is no biophysical explanation for metastatic site preference," said Peyton.
Peyton's second objective is to quantify integrin-mediated signaling pathways implicated in force transduction across breast cancer subtypes. Peyton said subtype-specific migration and proliferation of cancer cells depends on the ability of cells to activate force transduction pathways and generate intracellular tension. She said highthroughput biochemical signaling analysis techniques will be used to measure activation of key pathways implicated in force transduction and cytoskeletal assembly.
Her third objective is to build statistical models to discover signals that contribute to metastasis across combinations of cell type and extracellular matrix (ECM) composition. "Correlations between cell signaling and measured markers of metastasis exist and are detectable using a multivariable statistical framework," said Peyton. "Multivariable models based on robust statistical methods will be used to relate cell type, ECM composition, and signaling nodes contributing to cell migration, proliferation, and, therefore, poor patient prognosis."
Leonid Hanin, Ph.D., professor of mathematics and statistics at Idaho State University in Pocatello said he does not expect major breakthroughs from the engineering approaches to cancer, although some ideas and results may be useful. "Physical properties of cancer cells change with cell type and stage of cancer, so these differences and changes can be detected using the methods of engineering. What I like about the involvement of engineers, as well as mathematicians and physicists, in cancer studies is that they bring in an entirely different frame of thinking, which is so much different from that of biomedical scientists."
Hanin said although basic cancer biology and clinical oncology generated over the last several decades an enormous body of knowledge, its translational value is very small. "Most importantly, and ominously, cancer incidence and mortality for most types of cancer remain very high, and for some of them mortality continues to rise.
Michael Sheetz, Ph.D., director of the Mechanobiology Institute of Singapore, said we can expect to see engineering and other research disciplines-besides more "traditional medicine"-tackling tough issues such as metastasis and other aspects of cancer in the future. "The problem with most cancers is that the cells do not respond properly to the cues from the local microenvironment, and therefore, cancer cells need to be understood in terms of their 'mechanobiology'. The question is, how does a cancer cell avoid mechanical cues that should block its growth? That question cannot be answered with just biochemistry." Sheetz is also the William R. Kenan Jr. professor of cell biology at Columbia University in New York.
Hanin offered an important caveat about swinging too far into the mathematical-engineering camp of cancer research. "Another concern of mine is that designing mathematical models by engineers and their doing statistical analysis may be a recipe for disaster. This should be done by professional mathematicians and statisticians. I have read and reviewed hundreds of papers involving mathematical modeling and statistical data analysis, and in about 70% of cases what was done is totally wrong."
Peyton has established safeguards to ensure that does not happen. "Data of high confidence will be consistently produced, via collaboration between a completely experimental lab and one that focuses on developing and implementing statistical models and methods," she said. Lead author Ethan Halpern, M.D., codirector of Jefferson's Prostate Diagnostic Center, said as a result of the study, they found almost three times as many highergrade cancers by using half as many needle biopsies compared with systematic biopsy methods. "Today, a physician may sample 12-18 tissue cores from the prostate in order to help diagnose a patient. But with contrast-enhanced, that number drops to six or even less," said Halpern. "As a result, we believe CEUS could prove to be more efficient for screening clinically important cancers and monitoring low-risk ones with fewer biopsies." CEUS has been studied before. Two smaller studies, both conducted by researchers from the Medical University in Innsbruck, Austria-one in 2007 and the second in 2010-also concluded that CEUS improved prostate cancer detection. "Our study similarly confirms an increased frequency of positive cores in CEUStargeted biopsy compared to systematic biopsy by nearly double," said Halpern (16.4% vs. 8.5%.).
